U.S. FDA Slams Ranbaxy’s Claims In Nexium, Valcyte Lawsuit
This article was originally published in PharmAsia News
The U.S. drug regulatory agency highlighted Ranbaxy’s faulty manufacturing practices, strongly retaliating to its claims in a lawsuit challenging the recent decision to rescind tentative approvals for generic versions of Nexium and Valcyte. Among others, the FDA brought up a few strong points like how it had backed arguments in the past that led to Ranbaxy gaining exclusivity approvals on two drugs.
You may also be interested in...
Suit argues FDA granted tentative approvals of generic versions of Valcyte and Nexium to maintain Ranbaxy’s marketing exclusivity.
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.